December 9, 2020 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector.
The subcutaneous drug delivery system, currently in final phases of development, is designed as ready to use and to deliver drugs such as biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.
The research confirms that the BD Libertas device delivered within an acceptable time period 5 mL of 8 cP injections to the abdomen and thigh regardless of subject age, gender, or BMI and with/without patient movement, the company says.
The application, use, and removal of the injector were found to be acceptable and 100% of subjects were likely to use the BD Libertas Wearable Injector if prescribed. No severe wheal, erythema, or bleeding was observed, and no unacceptable pain was noted at 24 hours post-injection.
BD Libertas Wearable Injector is a product in development. BD Libertas Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance.